For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
2
views
2
references
 Top references
cited by
0
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
1 collections
    0
    shares
      2,853
      similar
       All similar
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Ethical concerns regarding heterologous COVID-19 vaccine administration

      letter
      Author(s): a , b
      Publication date (Electronic, pub):
      Publication date (Electronic, collection):
      Journal: Human Vaccines & Immunotherapeutics
      Publisher: Taylor & Francis
      Keywords: Covid, vaccine, ethic, heterologous

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Related collections

          Most cited references2

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          Heterologous mRNA-based COVID-19 booster strategies: Comment

          Sora Yasri, Viroj Wiwanitkit (2023)
          Article 0 comments Cited 2 times – based on 0 reviews     Review now
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Evidence synthesis and pooled analysis of vaccine effectiveness for COVID-19 mRNA vaccine BNT162b2 as a heterologous booster after inactivated SARS-CoV-2 virus vaccines

            Moe H. Kyaw, Julia Spinardi, Ling Zhang … (2023)
            Introduction of primary COVID-19 vaccination has helped reduce severe disease and death caused by SARS-CoV-2 infection. Understanding the protection conferred by heterologous booster regimens informs alternative vaccination strategies that enable programmatic resilience and can catalyze vaccine confidence and coverage. Inactivated SARS-CoV-2 vaccines are among the most widely used vaccines worldwide. This review synthesizes the available evidence identified as of May 26, 2022, on the safety, immunogenicity, and effectiveness of a heterologous BNT162b2 (Pfizer-BioNTech) mRNA vaccine booster dose after an inactivated SARS-CoV-2 vaccine primary series, to help protect against COVID-19. Evidence showed that the heterologous BNT16b2 mRNA vaccine booster enhances immunogenicity and improves vaccine effectiveness against COVID-19, and no new safety concerns were identified with heterologous inactivated primary series with mRNA booster combinations.
            Article 0 comments Cited 2 times – based on 0 reviews     Review now
              Bookmark
              All references

              Author and article information

              Journal
              Journal ID (nlm-ta): Hum Vaccin Immunother
              Journal ID (iso-abbrev): Hum Vaccin Immunother
              Title: Human Vaccines & Immunotherapeutics
              Publisher: Taylor & Francis
              ISSN (Print): 2164-5515
              ISSN (Electronic): 2164-554X
              Publication date (Electronic, pub): 14 February 2024
              Publication date (Electronic, collection): 2024
              Publication date PMC-release: 14 February 2024
              Volume: 20
              Issue: 1
              Electronic Location Identifier: 2313250
              Affiliations
              [a ]Private Academic and Editorial Consultant; , Bangkok, Thailand
              [b ]Department of Research Analytics, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences Saveetha University India;
              Author notes
              CONTACT Somsri Wiwanitkit somsriwiwan@ 123456hotmail.com Private Academic and Editorial Consultant; , Bangkok 103300, Thailand.
              Author information
              https://orcid.org/0000-0003-1039-3728
              Article
              Publisher ID: 2313250
              DOI: 10.1080/21645515.2024.2313250
              PMC ID: 10878430
              PubMed ID: 38353267
              SO-VID: 503373e7-0442-4c5d-9873-c1ff4e971c96
              Copyright © © 2024 The Author(s). Published with license by Taylor & Francis Group, LLC.
              License:

              This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License ( http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.

              History
              Related
              Page count
              Figures: 0, References: 2, Pages: 1
              Categories
              Subject: Letter to the Editor
              Subject: Coronavirus

              ScienceOpen disciplines: Molecular medicine
              Keywords: covid,vaccine,ethic,heterologous
              Data availability:
              ScienceOpen disciplines: Molecular medicine
              Keywords: covid, vaccine, ethic, heterologous

              Comments

              Comment on this article